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Background: Pulmonary hypertension (PH) frequently co-exists with severe aortic
valve stenosis (AS) and PH severity has been shown to predict long-term outcomes
after transcatheter aortic valve implantation (TAVI). The impact of PH etiology on
clinical outcomes after TAVI is unknown.
Methods: Of 606 consecutive patients undergoing TAVI, 433 (71.4%) patients with
severe AS and a pre-procedural right heart catheterization were assessed. Patients were
dichotomized according to whether PH was present (mean pulmonary artery [PA]
pressure 25mmHg) (n¼325) or not (n¼108). PH patients were further dichotomized
by left-ventricular end-diastolic pressure (LVEDP) into post-capillary (LVEDP >15
mmHG; n¼269) and pre-capillary groups (LVEDP 15 mmHg; n¼56). Finally, post-
capillary PH patients were divided into passive (n¼133) and reactive (n¼136) sub-
groups according to whether the transpulmonary gradient was normal (12mmHg) or
elevated (>12mmHg). Primary-endpoint was all-cause mortality at one year.
Results: PH was present in 325/433 (75%) patients and was predominantly post-
capillary (n¼269/325; 82%). Compared with baseline, PA systolic pressures imme-
diately improved after TAVI in post-capillary reactive (55.314.4 vs 48.415.5
mmHg, p< 0.001), but not pre-capillary (49.012.6 vs 51.614.3, p¼0.36) patients.
As compared with no PH, a higher rate of one-year mortality was observed in both
pre-capillary (hazard ratio [HR] 2.30, 95% conﬁdence interval [CI] 1.02-5.22,
p¼0.046) and reactive (HR 2.63, 95% CI 1.33-5.20, p¼0.006) but not passive PH
patients (p¼0.43). Following adjustment, reactive PH remained an independent pre-
dictor of one year mortality after TAVI (HR 2.52, p¼0.01).
Conclusions: Hemodynamic stratiﬁcation of PH by etiology predicts acute response
to treatment and long-term mortality after TAVI.
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Background: Conventional redo aortic valve replacement (AVR) is associated with
high mortality and morbidity, particularly in elderly patients. Transcatheter aortic
valve implantation (TAVI) is a less invasive and potentially lower-risk therapeutic
option. We sought to assess outcome of Valve-in-Valve (ViV) TAVI for failing
stentless AVR performed at our institution.
Methods: All 22 patients undergoing 22 ViV TAVI for failing stentless AVR per-
formed at our centre were included. Mean age 7412 years, logistic EuroScore
3810, all NYHA Class III/IV, 41% had chronic kidney disease, 36% had ascending
aorta calciﬁcation, 32% had patent coronary bypass grafts, 27% had previous PCI,
14% had pulmonary disease (TLCO < 30%), and 14% had previous stroke. Original
implant date ranged 1990 to 2006. All patients had severe aortic regurgitation (AR)
due to failing homograft (17), Toronto (3), Freestyle (1), or native re-suspended aortic
valve (1). Mean left ventricular ejection fraction was 5719%.
Results: ViV TAVI was performed electively in 7, urgently in 13, and emergently in 2
cases. All received a CoreValve (23mm device in 2, 26mm in 13, 29mm in 6, 31mm in
1). Access route was transfemoral (19), subclavian (2), and direct aortic (1). The device
was deployed too high in 1 case and too low in 2, necessitating TAVI-in-TAVI. In
2 cases, the device migrated high prior to full deployment, requiring lower re-
deployment. In 1 case, the device embolized into ascending aorta and required surgical
removal. 30-day mortality was 0%. Based on VARC-II deﬁnitions, rate of myocardial
infarction, tamponade, stroke, bleeding, acute kidney injury, and major vascular
complications were all 0%. New pacemaker implantation occurred in 14%. Para-
valvular AR was absent in 4, mild in 15, mild-moderate in 3. Average length of hospital
stay was 96 days, and all patients were discharged home. At long-term (1-55 month)
follow-up, 19 patients remained alive (3 deaths; 65 days, 7 months, 9 months).
Conclusions: ViV TAVI may be performed in high-risk patients with failing
stentless AVR. Lack of ﬂuroscopic markers increases risk of valve migration and
embolization. Despite this, 30-day mortality was 0%, with low morbidity, and reso-
lution of AR.
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Background: Transfemoral aortic valve implantation (TAVI) requires large bore
catheters. Access site and vascular complications, therefore are of concern. Beside
major vascular complications, post-TAVI pseudoaneurysm formation (PAF) is a
frequent minor vascular complication. The aim of the study was to compare the
incidence of post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-F-
sheath and the Edwards Sapien XT valve (ESV) using the 16-20 F Esheath.
Methods: Between April 2010 and December 2013, 448 pts (age 81.2  0.4 years)
with high surgical risk (Euroscore 24.3  0.8%) underwent successfully TAVI in local
anesthesia using either the CV (23,26,29,31mm) or the ESV (23, 26, 29mm). Closure
of the access site was perfomed in all pts by using the ProStar XL 10 suture device. All
TAVI pts (357 CV and 91 ESV) were examined serially the ﬁrst 5 days (day 1-3 and 5
post-TAVI) after the procedure by ultrasound (US) for clinically silent vascular
complications. In case of PAF, ultrasound-guided manual compression was done
followed by compression bandage for another 24 h.
Results: In 26 pts (5.6%) we observed major vascular complication after TAVI (19
[5.3 %] after CV and 7 [7.7%] after ESV, p¼0.261). Seven of these 26 pts (26.9%)
had to be treated surgically. In 78 pts (17.4%) we observed post-TAVI PAF, which
occurred signiﬁcantly more frequently after implantation of the ESV than after im-
plantation of the CV (19/91 [33.0%] versus 59/357 [16.6%], p¼0.01). However in
total only 5 /78 (6.4 %) patients with PAFs had to be treated surgically , the others
were treated either by ultrasound guided manual compression or conservatively if
smaller than 1 cm.
Conclusions: Clinically silent PAF detected by routine US is a frequent post-TAVI
minor vascular complication which is more likely to occur after ESV using the
Esheath than after CV. Although US-guided compression is highly effective, further
miniaturisation of TAVI devices and modiﬁcation of the Esheath design might help to
eliminate post-TAVI PAF.
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Background: The successful TAVI outcomes are partly driven by the operator skills,
expertise & experience. The impact of “learning curve” on one year all-cause mor-
tality is not well understood.
Methods: Registry records of 188 consecutive TAVI cases in a UK tertiary cardiac
centre (2007-2013) were reviewed using patient-level data. One year all-cause mor-
tality data was collated with demographic, risk proﬁle and TAVI procedural infor-
mation. Kaplan-Meier analysis was used to compare mortality among the ﬁrst 60
patients(learning curve group,GP1) with age, gender matched sequential groups(GP2,
n¼64 & GP3, n¼64)tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Mean age was 82(SD:6 yrs) & 50% were male.Median Euroscore was
17(IQR 10-22).Smoking (54%) and diabetes (20%) were the most common cardiac
risk factors.Access route of choice was femoral (94%). Medtronic Corevalve was used
most commonly (68%).Permanent pacing was required in 18% of patients & 9% had
at least one major complication.Event free survival was signiﬁcantly higher (92% vs.
65%) in the later time periods (GP 2 and 3: n¼128) compared to that in the “learning
curve” group (GP1: n¼60), (log rank p¼0.003),(graph 1).There was a 50% reduction
in index procedure hospital stay for the latest cohort compared to the ﬁrst two
cohorts (GP1 & 2 median ¼ 8 days, IQR 4-16 days),(GP3:median:4 days,IQR
3-9 days),(p¼0.002).
Conclusions: One year all-cause mortality has improved and hospital stay has reduced
over three consecutive time periods.The mortality reduction does not relate to patient
characteristics and may have been driven by acquired skills and experience of the
TAVI team and advances in valve designs
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Background: Transcatheter aortic valve implantation (TAVI) has become the stan-
dard intervention for elderly patients with aortic stenosis. Implantation of the valve
without pre-dilatation might have some advantages by reducing procedural steps and
thereby also the complication rate. This has been demonstrated for the antegrade
transapical access with the ballon-expandable Edwards SAPIEN XT valve. However,
the feasibility of TAVI with a balloon expandable device without predilatation using
the retrograde transfemoral route has not been evaluated yet.
Methods: Twenty six consecutive patients with stenosis of the native aortic valve
undergoing transfemoral TAVI with the Edwards Sapien XT prosthesis were enrolled
in this study.
Results: The procedure was successfully performed in all 26 patients - irrespective of
the aortic valve area and the extent of aortic valve calciﬁcation. At baseline mean
aortic valve area, mean AV gradient and median LVEF were 0.7  0.2 cm2, 36.0 
17.3 mmHg and 55.0% [IQR 35.0 – 60.0]; prior to discharge these values changed as
follows: 1.7  0.3 (p < 0.001), 9.8  6.1 mmHg (p < 0.001) and 57.5% [IQR 38.7 –
60.0] (p ¼ ns). Postdilatation due aortic regurgitation > 2 was required in 3 cases,
leading to aortic regurgitation < 2 in all patients. Of note, no periprocedural
neurological adverse events occurred.
Conclusions: Transfemoral aortic valve implantation without pre-dilatation using the
Edwards Sapien XT is feasible and safe.
TCT-741
Risk Stratiﬁcation and Clinical Pathways Optimize Length of Stay after
Transfemoral Transcatheter Aortic Valve Replacement
Sandra Lauck1, David A. Wood2, Anson Cheung3, Richard Cook4, Danny Dvir5,
Mathieu Lempereur6, Imran A. Shiekh6, Dion Stub7, John Webb2, Peter Fahmy8,
Jian Ye9
1St. Paul’s Hospital, Vancouver, BC, 2University of British Columbia, Vancouver,
Canada, 3St Pauls Hospital, Vancouver, British Columbia, 4St. Paul’s Hospital.
University of british Columbia, Vancouver, British Columbia, 5St Paul’s Hospital,
Vancouver, Canada, Vancouver, Canada, 6Vancouver General Hospital, Vancouver,
British Columbia, 7Baker IDI Heart and Diabetes Institute, Melbourne, Australia,
8Centre for Heart Valve Innovation, Vancouver, British Columbia, 9St Paul’s
Hospital, Vancouver, British Columbia
Background: The Vancouver Program initiated multidisciplinary and multimodality
risk stratiﬁcation to determine patients’ suitability for a transfemoral (TF) minimalist
peri-procedural approach, and implemented risk-stratiﬁed clinical pathways to facili-
tate discharge and reduce length of stay.
Methods: Standardized screening was implemented to conduct multimodality as-
sessments. Following multidisciplinary eligibility decision for TF TAVR by the Heart
Team, additional risk stratiﬁcation was discussed to determine individuals’ appro-
priateness for the peri-procedural “General Anaesthesia and Transesophageal Echo-
cardiography” (“GA/TEE”) and “Awake” (e.g., local anaesthesia) protocols, and the
planning requirements for standard (post-procedure day 3) and early (post-procedure
day 1-2) discharge protocols. Risk-stratiﬁed clinical pathways were developed to
support the patient cohorts.
Results: 144 consecutive patients were accepted for TF TAVR and assigned to risk-
stratiﬁed protocols. The mean age was 827 years, with the proportion of women
ranging from 37% to 42%, and mean STS risk scores between 6.3 and 7.1 in the 4
cohorts. The overall in-hospital outcomes included 2.1% mortality, 0% myocardial
infarction, 0.7% stroke, 2.1% life threatening bleeding, 0.7% new dialysis, and 4.2%
conduction disturbances requiring a new permanent pacemaker. The median length of
stay for all patients was 3 days (IQR 2-3), 2 days (IQR 1-3) in the Awake cohort and 2JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Va(IQR 1-2) in the Early Discharge cohort; 95.8% of patients were discharged home.
The 30-day all-cause hospital readmission rate was 11.1%, ranging from 7% and 8%
in the Awake and Early Discharge cohorts respectively, to 13% in the GA/TEE and
Regular Discharge cohorts; no new deaths occurred between discharge and 30 days.
Conclusions: Early experience with TAVR risk stratiﬁcation, individualized proce-
dure planning and tailored clinical pathways supported by multimodality screening
and multidisciplinary case selection and care results in excellent outcomes and opti-
mized length of stay.
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Background: Chronic kidney injury (CKD) seems to affect survival after TAVI, but
inconsistency in data exists. On the contrary, acute kidney injury (AKI) after TAVI is
prevalent and more clearly associated with mortality. However, an improvement in
serum creatinine is also prevalent after TAVI, possibly due to an improved renal blood
ﬂow. We analyzed the effects of an improved serum creatinine on prognosis in pa-
tients with and without CKD undergoing TAVI.
Methods: All patients undergoing TAVI in our centre for whom multiple serum
creatinine measurements after TAVI were available were prospectively enrolled from
June 2007 to December 2013. CKD was deﬁned as a glomerular ﬁltration rate <
60ml/min. Serum creatinine was measured before and after TAVI. The ratio of the
highest creatinine value after TAVI to before TAVI (CRR) was calculated. A CRR <
1.0 was deﬁned as an improvement, and a CRR 1.5 as AKI, further divided ac-
cording to the AKIN classiﬁcation.
Results: In total, TAVI was performed on 196 (mean age 82.16.4, male 42%, lo-
gistic EuroSCORE 26.916.6%) and 218 (mean age 79.97.5, male 45%, logistic
EuroSCORE 23.815.1%) patients with and without CKD, respectively. In the CKD
group, CRR was < 1.0, 1.0-1.5, and 1.5 in 98 (50.0%), 70 (35.7%) and 28 (14.3%)
of patients, respectively. In the group with normal renal function, CRR was < 1.0, 1.0-
1.5, and 1.5 in 85 (38.9%), 108 (49.5%) and 25 (11.5%) of patients, respectively.
AKI was an independent predictor for early and late mortality. An improvement of
renal function was a negative independent predictor for 2-year mortality in patients
with CKD (HR 0.28, 95% CI 0.15 to 0.51, p< 0.001) but not for patients without
CKD (HR 0.70, 95% CI 0.41 to 1.20, p¼0.19).
Conclusions: The occurrence of AKI is an independent predictor for mortality after
TAVI in patients with and without CKD. However, an improved renal function after
TAVI predicts long-term survival only for patients with prior CKD.
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Background: The aim of this study was to compare the outcomes of transcatheter
aortic valve implantation (TAVI) with the Medtronic CoreValve Revalvivng System
(MCV) with or without preparatory balloon aortic valvuloplasty (PBAV).
Methods: From November 2007 to September 2013 all patients treated with MCV
were included in this analysis. Patients were divided in 2 groups: those where PBAV
was performed and those where MCV was directly implanted. PBAV was performed
according to operator descretion, after consideration of patient anatomical character-
istics. Outcomes were assessed according to valvular academic research consortium
(VARC-2) criteria at 30 days and 1 year.
Results: Of 538 patients that underwent TAVI in our center, 206 were treated with a
MCV via one of the available access routes. Of those, 133 underwent PBAV, while 73
direct valve implantation. Baseline characteristics between the 2 groups were similar.
At 30 days there were no signiﬁcant differences in all-cause and cardiovascular
mortality (3% vs. 5.5%, p ¼ 0.380; and 1.5% vs. 5.5%, p ¼ 0.105; respectively). A
trend for a higher incidence of cardiac tamponade (2.4% vs. 7.8%; p ¼ 0.078) and a
signiﬁcantly higher rate of at least moderate peri-prosthesic aortic regurgitation
(PPAR) requiring valvular balloon post-dilation (VBPD; 35.6% vs. 49.3%, p¼ 0.056)
was noted amongst patients where PBAV was not performed. Conversely patients
who underwent PBAV had more AKI (32.3% vs. 19.4%; p ¼ 0.049). No signiﬁcantlvular disease - Aortic: TAVR B217
